FBIO
Fortress Biotech, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-31
Figures on this page computed 2026-11-08 12:40 UTC
Last close
1.97USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-03-31
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-31
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-13
10.8%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-13
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Safety is the furthest below its sector's middle: 0.37 against 0.52 on the market's range.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 3- Profit on each unit of sales10.8%-13.0%Ahead
Higher is better here.
- Return on the capital it usesn/an/an/a
Higher is better here.
- Sales growth over five years6.8%11.8%Behind
Higher is better here.
- Debt against equityn/an/an/a
Lower is better here.
- Gross margin66.9%73.3%Behind
Higher is better here.
- Price against earningsn/an/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Heron Therapeutics, Inc., FBIO is behind on 2 of 3 measures.
Against Heron Therapeutics, Inc., FBIO is behind on 2 of 3 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-31
Profit on each unit of sales10.8%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
Sales growth over five years6.8%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
Debt against equityn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
Gross margin66.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001104659-26-037874
- Reported in
- USD